Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study aims to redefine Lung-Heart disease

NCT ID NCT02980887

Knowledge-focused Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study looks at nearly 1,200 people with or at risk for pulmonary hypertension (high blood pressure in the lungs). Researchers use many advanced tests to find new ways to classify the disease and identify biomarkers. The goal is to better understand the disease and improve future diagnosis and treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,195 people

The number who actually took part.

Start date

Nov 2016

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with pulmonary hypertension, Pulmonary hypertension vascular, and healthy controls

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Cross-sectional (parent) study: Inclusion Criteria: Patients ages \>18 years of age referred for right heart catheterization for further evaluation of known PVD or to be at risk for PVD due to established cardiac disease or pulmonary disease * Able to perform complete diagnostic testing listed subsequently (cardiac catheterization, echo, exercise test, PFT's, ECG, chest CT, quality of life questionnaires, ventilation/perfusion scan, cardiac MRI, body composition bioimpedance, and sleep study) * Subject signs informed consent to perform required testing for the protocol Exclusion Criteria: Dialysis dependent renal function; In the clinician's opinion, too ill to perform the protocol testing; Pregnant or nursing Longitudinal study: Inclusion Criteria: * Any PH, comparators or control participant previously enrolled in the parent PVDOMICS protocol with a minimum of six months post-enrollment * Dialysis dependent renal function since the parent study acceptable Exclusion Criteria: Participant Level 1 (clinic visit): * Transplant other than heart or lung * In the clinician's opinion, too ill to perform L-PVDOMICS testing even if limited testing. * Participants who withdrew from the parent PVDOMICS study * Pregnant or nursing * Concurrent participation in any investigational drug study or other clinical trial Participant Level 2 (telephone visit): * Transplant other than heart or lung * Participants who withdrew from the parent PVDOMICS study Participant Level 3 (medical chart review): \- Participants who withdrew from the parent PVDOMICS study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary arterial hypertension

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland, 21287, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • New York Medical College

    Valhalla, New York, 10595, United States

  • University of Arizona Health Sciences Center

    Tucson, Arizona, 85721, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Weill Cornell Medicine

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.